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| INTRODUC TI ON
A premature ventricular complex (PVC) is defined as early electric depolarizations originating in the ventricular myocardium. PVCs are often seen on electrocardiography irrespective of cardiac diseases, and are commonly considered to be benign. 1, 2 However, it has been demonstrated that frequent PVCs not only cause various types of disease symptoms such as palpitations, atypical chest discomfort, and syncope but also contribute to cardiac remodeling and subsequent heart failure (HF). 1, 3 Recent therapeutic advances improve clinical outcome of HF patients. However, the high rate of re-hospitalization and high cardiac mortality are still serious issues. 4 The frequency of PVCs is considered to be higher in HF patients compared with general populations. 5 However, the relationship between PVC burden and the progression of HF has not been fully elucidated. It was previously reported that an increasing PVC burden of >24%/d on 24 hours Holter monitoring was significantly related with left ventricular (LV) remodeling in the patients with idiopathic PVCs undergoing radiofrequency catheter ablation (RFCA). 6 On the other hand, in HF patients, even a low-PVC frequency may have a significant impact on LV dysfunction and poor prognosis. Thus, we aimed to validate the clinical significance of PVC burden on cardiac function, exercise capacity, and outcome in hospitalized patients with HF.
| ME THODS

| Subjects and study protocol
This study consisted of 435 patients hospitalized with decompensated HF at Fukushima Medical University Hospital between 2010
and 2015. The diagnosis of decompensated HF was determined by several physicians using the HF guidelines. 7, 8 All subjects received optimal medication for HF and underwent echocardiography, 24 hours Holter monitoring and cardiopulmonary exercise testing at stable condition before discharge. Before study enrollment, 23 patients had undergone implantable cardioverter defibrillator (ICD, n = 10), cardiac resynchronization therapy (CRT)-pacemaker (CRT-P, n = 3), or CRT-defibrillator (CRT-D, n = 10) in accordance with established criteria. 9, 10 The exclusion criteria in our study were acute coronary syndrome and receiving hemodialysis. The methodology of the present study has been validated in our previous work. 11 All subjects gave written informed consent. The study protocol was approved by the ethics committee of Fukushima Medical University (approval number: 1656).
| Determination of risk factors
The definition of target comorbidities (ie, hypertension, diabetes, dyslipidemia, chronic kidney disease, and anemia) was mentioned in a previous work. 11, 12 The definition of hypertension was the recent use of antihypertensive medications, a systolic blood pressure of ≥140 mm Hg, and/or a diastolic blood pressure of >90 mm Hg. 13 The definition of chronic kidney disease was an estimated GFR of <60 mL/min/1.73 m. 13, 14 The definition of anemia was hemoglobin of <12.0 g/dL in women and <13.0 g/dL in men.
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| Identification of cardiac events during the follow-up
The 
| Echocardiography
Echocardiography was performed using standard techniques by experienced echocardiographers using an ultrasound system (ACUSON Sequoia, Siemens Medical Solutions USA, Inc) at our hospital. 15 Interventricular septum thickness, posterior wall thickness, and LV end-diastolic diameter were measured in parasternal long axis view at end diastole. LV end-systolic diameter and left atrial (LA) dimension were measured in parasternal long axis view at end systole. LV ejection fraction (LVEF) was assessed using the modified Simpson's method. 
| Holter monitoring
| Cardiopulmonary exercise testing
The patients underwent incremental symptom-limited exercise testing using an upright cycle ergometer with a ramp protocol (Strength Ergo 8; Fukuda Denshi). Breath-by-breath oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), and minute ventilation (VE)
were assessed during exercise using an AE-300S respiratory monitor (Minato Medical Science). 17 Peak VO 2 was measured as an average of the last 30 seconds of exercise. Ventilatory response to exercise (expressed as a VE/VCO 2 slope) was calculated as the regression slope relating VE to CO 2 from the start of exercise until the respiratory compensation point (the time at which ventilation is stimulated by CO 2 output and end-tidal CO 2 tension begins to decrease). 
| Statistical analysis
Parametric variables were presented as mean ± SD, nonparametric variables were presented as a median and interquartile range, and categorical variables were expressed as numbers and percentages. Parametric variables were compared using Student's t test, nonparametric variables were compared using the Mann-Whitney U test, and the chi-square test was used for comparisons of categorical variables. The correlation relationships were investigated by Spearman's rank correlation coefficient. The Cox proportional hazard regression models determined which variables were associated with cardiac events. In addition to the electrocardiographic parameters, to prepare for potential confounding, we considered the following clinical factors, which are generally known to affect prognosis in patients with HF: age, sex, comorbidities, and treatment. The variables selected for testing in the multivariable analysis were those with a P < .05 in the univariable models. Sensitivity, specificity, areas under the receiver-operating characteristic (ROC) curve, and the optimal cutoff value for identification of cardiac events at the 1-year follow-up were calculated using ROC analysis.
In the follow-up period, Kaplan- 
| RE SULTS
| Baseline characteristics
The baseline characteristics of the present study's subjects are summarized in Table 1 . There were 125 (28.7%) cardiac events including appropriate ICD therapy (n = 5), re-hospitalization due to worsening HF (n = 71), or cardiac death (n = 49) due to HF (n = 37), ventricular fibrillation (n = 4), and sudden death (n = 8) during a median followup period of 2.3 years. Compared to the noncardiac event group, the cardiac event group had a higher prevalence of NYHA class III/ IV, hypertension, diabetes, chronic kidney disease, anemia, receiving device therapy (ICD, CRT-P, or CRT-D), as well as intake of ACE inhibitors/ARBs and amiodarone. In addition, age and PVC burden were significantly higher, and LVEF was significantly lower in the cardiac event group than in the noncardiac event group. However, gender, prevalence of ischemic etiology, dyslipidemia, and other medications
were not different between the two groups.
| Predictive impact of PVC burden on cardiac events
The ability of variables to predict cardiac events was examined by the univariable and multivariable Cox proportional hazard analyses, and the data are shown in Table 2 In ROC analysis, the optimal cutoff value of PVC burden for predicting cardiac events at the 1-year follow-up was 0.145%/d (95% CI:
0.570-0.714, P < .001, sensitivity of 64.2%, specificity of 59.0%, and areas under the curve of 0.64). The study subjects (n = 435) were then divided into two groups: high-PVC burden (>0.145%/d, n = 194) and low-PVC burden (n = 241). The patients with high-PVC burden had higher prevalence of NSVT and multifocal PVCs, LV and LA dilatation, lower LVEF, and impaired exercise capacity, compared to the patients with low-PVC burden, as shown in Table 3 . Furthermore, PVC burden was negatively correlated with LVEF and peak VO 2 (R = −.247, P = .005
and R = −.139, P = .035, respectively) and positively correlated with LV end-diastolic diameter and LA dimension (R = .328, P < .001 and R = .156, P = .002, respectively). During a median follow-up period of 2.3 years, cardiac event-free survival was significantly lower in the high-PVC burden group than in the low-PVC burden group (P < .001),
as shown in Figure 1 . We conducted subgroup analyses and examined interaction terms to assess potential heterogeneity of impact of high-PVC burden (>0.145%/d: vs low-PVC burden) on cardiac events (Table 4 ). The univariable analysis showed that high-PVC burden was significantly associated with cardiac events with a HR of 2.028 (95% CI: 1.418-2.901, P < .001). There were no interactions except for a significant interaction with presence of hypertension (P = .015) or anemia (P = .049), and prescribed ACE inhibitors/ARBs use (P = .028) in associations of high-PVC burden and cardiac events between subgroups.
Although the cardiac event group had a higher intake of amiodarone compared with the noncardiac event group in Table 1 , there was no significant interaction with an intake of amiodarone (P = .245) in association of high-PVC burden and cardiac events.
| D ISCUSS I ON
In the present study, there were several important findings. High-PVC burden (>0.145%/d) was significantly associated with an increased risk of cardiac events in hospitalized patients after optimal medication for HF. The patients with high-PVC burden had LV and LA dilatation, reduced LVEF, and impaired exercise capacity when compared to the patients with low-PVC burden (≤0.145%/d).
In subgroup analyses, the impact of high-PVC burden on cardiac events was found to be more distinct in HF patients without hypertension or anemia (HR 8.366, P < .001 and HR 3.209, P < .001, respectively).
TA B L E 1 Comparison of clinical characteristics between cardiac and noncardiac events
| Impact of PVC on HF patients
It has been considered that suppression or elimination of PVCs using β-blocker therapy and RFCA is an effective strategy to reverse cardiac remodeling with frequent PVCs. 19, 20 Therefore, PVC may have a significant impact on the progression of LV dysfunction, resulting in poor prognosis. Indeed, in the current study, our Cox hazard analysis revealed that high-PVC burden is significantly associated with an increased risk of cardiac events in hospitalized patients with HF. In HF patients, the frequency of PVCs is increased by the impaired oscillation of sympathetic 21 or vagal activity. 5, 22 In addition, it has been demonstrated that cardiac autonomic dysfunction, such as impaired heart rate turbulence in stable compensated HF, is associated with readmission due to worsening HF and high cardiac mortality. 11 Thus, the patients with frequent PVCs after optimal medication for HF may be associated with high risk of cardiac events.
In the present study, the multivariable analysis indicated that LVEF was not an independent predictor of cardiac events. One possible reason for this result was that LVEF of our study was not severely reduced (46.0 ± 16.6%). Although LVEF is a powerful predictor of cardiovascular events, a previous study demonstrated that cardiovascular death declined with increasing LVEF up to 45%. 23 In addition, it has been reported that the majority of deaths in HF with preserved ejection fraction are cardiovascular deaths. 
| Relation of PVC burden to the progression of HF
It was previously demonstrated that an increased PVC burden was related with LVEF reduction and LV dilatation assessed by echocardiography in patients with idiopathic PVCs undergoing RFCA. 25 In another Abbreviations: CI, confidence interval; HR, hazard ratio. The other abbreviations are as in Table 1 . a Continuous variables.
TA B L E 2 Univariable and multivariable
Cox proportional hazard models for predicting cardiac events study, non-HF patients with high-PVC burden (0.123%-17.7%/d) had a 48% increased risk of incident HF and a 31% increased risk of mortality over a median follow-up >13 years compared with those with low-PVC burden (0%-0.002%/d). 26 In the present study, the HF patients with a PVC burden of >0.145%/d had reduced LVEF, dilated LV and an increased incidence of appropriate ICD therapy, readmission, and cardiac mortality during a median follow-up period of 2.3 years compared with those with a PVC burden of ≤0.145%/d. Therefore, in the HF patients, even a low-PVC frequency might be associated with adverse events in a short time compared with non-HF patients.
In addition, the HF patients with high-PVC burden also had a higher prevalence of NSVT and multifocal PVCs, LA dilatation, and impaired exercise capacity compared with those with low-PVC burden. The prevalence of NSVT and multifocal PVCs is associated with the development of cardiac death attributed to HF. 27, 28 LA overload due to LV dysfunction leads to LA enlargement, and LA remodeling is an independent predictor of mortality. 29, 30 Although the exercise capacity of HF patients with frequent PVCs has not been fully investigated, exercise capacity is generally considered to be a powerful predictor of mortality. 31 Therefore, although the frequency was low (>0.145%/d),
HF patients with high-PVC burden after administration of optimal medication had higher risk of cardiac events during follow-up period.
In subgroup analyses, significant associations between high-PVC burden and cardiac events were found in HF patients without hypertension or anemia. We could not fully explain the reason of these interaction. However, these associations may be explained by the fact that hypertension and anemia are important predictive factors of worsening HF. 32, 33 Also, the usage of ACE inhibitors/ARBs might be associated with cardiac events because there was a significant interaction with hypertension in associations of high-PVC burden and cardiac events.
One possible mechanism responsible for HF progression due to
PVCs is LV dyssynchrony. LV mechanical alterations due to the irregular beats of frequent PVCs can lead to increases in the LV filling pressure and the LA overload, resulting in the progression of HF in the general population. 34 However, it has been considered that LV dilatation due
to idiopathic PVCs appears to be a reversible and functional abnormality. 19, 20 In this study, we found that PV burden after optimal medication was an important predictor of cardiac events in hospitalized patients with HF. In addition, PVC burden was negatively correlated Abbreviations: CI, confidence interval; HR, hazard ratio. The other abbreviations are as in Table 1 and Table 3 .
TA B L E 4 Subgroup analyses for cardiac events: the impact of PVC burden high vs low
| Limitations
There are some limitations in this study. First, the present study was performed in a single institution with a relatively small number of subjects. Second, since only the baseline data at hospital discharge were used for the analyses, any changes after discharge in any parameters including Holter monitoring were not considered. Finally, we have performed both subgroup and multivariable Cox proportional hazard analyses and statistically adjusted differences in clinical backgrounds to validate a clinical impact of PVCs. However, these differences between the two groups might not be completely adjusted. Therefore, it remains unclear whether small amount of PVCs contribute to the pathophysiology of progressive HF or it functions merely as a marker of the progression of HF. We would consider performing a study on these issues in the future.
| CON CLUS IONS
The assessment of PVC burden after optimal medication is useful for predicting appropriate ICD therapy, readmission due to worsening HF, or cardiac death in hospitalized patients with HF. Although the frequency is low (>0.145%/d), PVC burden is an important predictive factor of cardiac events in patients with HF.
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